GeoVax Labs and Vivalis join hands for HIV vaccine development

Tue. July 22, 2008; Posted: 09:48 AM

Jul 22, 2008 (Datamonitor via COMTEX) -- GOVX | Quote | Chart | News | PowerRating -- GeoVax Labs and Vivalis have signed a letter of intent for joint collaboration and commercial license on the use of Vivalis's EBx technology, to manufacture the MVA component of the GeoVax HIV-1 vaccine.

The GeoVax vaccine is a DNA/MVA vaccine that uses recombinant DNA to prime the immune response and then a recombinant MVA virus to boost the immune response. MVA stands for modified vaccinia ankara, a smallpox viral vaccine that was attenuated by replicating the vaccine virus over 500 times in chicken cells.

The breakthrough manufacturing technology developed by Vivalis, and now to be further developed through collaboration with GeoVax, is expected to create a new standard for manufacture of the MVA component of the GeoVax HIV/AIDS vaccine, making present manufacturing technologies which have limited production capabilities, less competitive.

Financial terms of the agreement have not been disclosed. However, each side shall fund its roles respectively, depending on developmental or process responsibilities assumed by each party. An upfront amount payable to Vivalis will be provided as consideration for the signing of the letter of intent. GeoVax's development and license payments shall be made based on milestone achievements. Royalties on GeoVax net sales are also included.

In addition, applications have been filed for EU and local government financial participation. GeoVax is also seeking the FDA guidance on the Vivalis EBx manufacturing program recently submitted to the FDA allowing usage of EB66 produced MVA vaccine for GeoVax's ongoing human trials.

Franck Grimaud, Vivalis CEO, said: "This agreement aims at developing a Vivalis proprietary upstream-downstream process for the production of MVA vaccines and EBx technology licensing. GeoVax becomes a strategic partner and joins a worldwide consortium in the field of development, purification and production of MVA based vaccines."

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

For full details for GOVX click here.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

Tax Relief Bank Levy Wage Garnishment

Disclaimer:

The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.

It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.

HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.

The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.